AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03045055 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endovascular treatment.
Description: Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
Study NCT03045055 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
Study NCT01532583 — intervention group
Intervention type: OTHER
Intervention: Gynaecological examination, a supine stress test, questionnaires
Description: Gynaecological examination, a supine stress test, questionnaires
Study NCT03695198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237 - SC
Description: LY3361237 administered SC
Study NCT03695198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237 - IV
Description: LY3361237 administered IV
Study NCT03695198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Placebo administered SC
Study NCT03695198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Placebo administered IV
Study NCT03038945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2/0 barbed suture
Description: Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
Study NCT03038945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0/0 Vicryl suture
Description: Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
Study NCT03053115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Cases will take liothyronine drops in the morning and two hours after dinner
Study NCT03872388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
Study NCT03872388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
Study NCT03455296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid therapy; crystalloid
Description: maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
Study NCT03233061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiorespiratory fitness and daily physical activities evaluations
Description: The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine.
Study NCT03233061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiorespiratory fitness and daily physical activities evaluations
Description: The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine.
Study NCT00582530 — intervention group
Intervention type: OTHER
Intervention: Whole Blood Draw
Description: The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
Study NCT04095221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: DOSE LEVELS FOR PATIENTS > 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days
Study NCT04095221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 15 mg/m2 IV daily x 10 days in 21 day cycles
Study NCT01332396 — intervention group
Intervention type: DRUG
Intervention: Lapatinib
Study NCT01899066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis, chemotherapy
Description: Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Study NCT01899066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg oral tablet once daily for 24 weeks
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to sitagliptin oral tablet once daily for 24 weeks
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gliclazide
Description: Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
Study NCT01590771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
Study NCT02712671 — intervention group
Intervention type: RADIATION
Intervention: Chest radiograph
Description: A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
Study NCT03024684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg daily
Study NCT03053115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
Study NCT03024684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo one tablet daily
Study NCT04167631 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Multi-parametric MRI
Description: Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
Study NCT02712671 — intervention group
Intervention type: PROCEDURE
Intervention: Blood interferon gamma release assay
Description: Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
Study NCT02712671 — intervention group
Intervention type: PROCEDURE
Intervention: Tuberculin skin testing (TST)
Description: An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
Study NCT02712671 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum induction for mycobacterial microscopy and culture
Description: Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
Study NCT02712671 — intervention group
Intervention type: OTHER
Intervention: Mycobacterium tuberculosis polymerase chain reaction testing
Description: Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
Study NCT02712671 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
Study NCT02057289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
Study NCT01127217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/losartan
Description: amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
Study NCT01127217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
Study NCT05114694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early APM
Description: Early APM group were patients have knee syndrome within 3 to 6 months
Study NCT05114694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: delayed APM
Description: delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
Study NCT01108835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive care programme
Description: Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries.
Study NCT02882711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
Study NCT00778284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
Study NCT00778284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
Study NCT00184483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein's operation
Description: Lichtenstein's operation to repair primary unilateral inguinal hernia
Study NCT00184483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Hernia System
Description: Prolene Hernia System to repair primary unilateral inguinal hernia
Study NCT04172493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Endoscopy (HySE)
Description: Undergo hyperspectral endoscopy
Study NCT04172493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White Light Endoscopy (WLE)
Description: Undergo white light endoscopy
Study NCT04482829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing-yan-kang Granule
Description: Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
Study NCT04482829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PC chemotherapy and symptomatic treatment
Description: Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used.
Study NCT04482829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC chemotherapy and symptomatic treatment
Description: Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used.
Study NCT02479516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Assessment Program Philippines (CHAP-P)
Study NCT01909570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer
Description: After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
Study NCT01909570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double embryo transfer
Description: After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
Study NCT01914809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: samples blood
Study NCT01914809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples blood
Study NCT01914809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biopsy placentaire
Study NCT01914809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy placentaire
Study NCT00332332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: etanercept subcutaneous injection
Study NCT02200939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioinductive implant
Study NCT02200939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical repair
Description: Surgical repair with commercially-available sutures/suture anchors.
Study NCT01806740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B: Pramipexole Slow release (SR) tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H: Pramipexole Slow release tablet
Study NCT02261090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole immediate release (IR) tablets
Study NCT00753883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 20 mg/QD for 6 Weeks.
Study NCT00753883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/QD for 8 weeks.
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study NCT03053115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
Study NCT03053115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Controls will take placebo two hours after dinner
Study NCT01257763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Microchannel Skin System
Description: A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
Study NCT01257763 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 3
Description: Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study NCT01332890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)